Intercell and Novartis collaborate on Pseudomonas vax

Intercell and Novartis are continuing to test an investigational vaccine for Pseudomonas aeruginosa. The disease can cause nosocomial infections that lead to pneumonia and other infections, usually during hospital stays, particularly in patients on ventilators. The 400-patient efficacy trial should start in the first half of 2012. Intercell release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.